Currently, several ongoing clinical trials are aimed at evaluating the efficacy of cannabinoids as an adjunctive to PE therapy in PTSD patients, such as the study NCT03518801, which explores the effects of CBD, and the EudraCT 2020-001965-36, which explores the effects of a FAAH inhibitor. The gene discussed is FAAH; the disease is post-traumatic stress disorder.